Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

Abstract Background Large type 3 and type 4 gastric cancers have extremely poor prognoses. To address this, neoadjuvant chemotherapy may be a promising approach. The phase III JCOG0501 study, conducted to confirm the superiority of neoadjuvant S-1 plus cisplatin followed by D2 gastrectomy over upfro...

Full description

Bibliographic Details
Main Authors: Shunji Endo, Tetsuji Terazawa, Masahiro Goto, Ryo Tanaka, Takeshi Kato, Kazumasa Fujitani, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshimasa Tsujinaka, Toshio Shimokawa, Taroh Satoh
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Cancer
Subjects:
Stomach Neoplasms
Docetaxel
Oxaliplatin
S-1
Neoadjuvant Therapy
Large type 3
Online Access:https://doi.org/10.1186/s12885-022-09890-w

Internet

https://doi.org/10.1186/s12885-022-09890-w

Similar Items